Table 2.
Pharmacologic and genetic mediators of Wnt/β-catenin signaling in chronic kidney disease.
| Pharmacologic | Mechanism | Effect | Ref |
| ICG-001 | Competitively binds CBP to prevent β-catenin/CBP binding to TCF | Reduced fibrosis in models of IRI, UUO, and in vitro models of CKD | 52, 65 |
| DKK-1 | Binds to LRP5/6 to prevent dimerization with Frizzled and Wnt binding | Reduced fibrosis and pericyte activation in UUO models of CKD | 25, 74 |
| Klotho | Binds to and sequesters Wnt ligands | Reduced fibrosis in UUO models of CKD | 83 |
| XAV939 | Stabilizes Axin to activate destruction complex and stimulate β-catenin degradation | Reduced myofibroblast activation in vitro models of CKD | 69, 84 |
| sFRP4 | Binds Wnt and Frizzled to disrupt signaling functions | Reduced fibrosis in UUO models of CKD | 69 |
| C59 | Binds Porcupine to prevent acylation and secretion of all Wnts | Reduced fibrosis in UUO models of CKD | 67 |
| Pyrvinium | Inhibits axin degradation, which stimulates p-catenin degradation | Reduced fibrosis and myofibroblast markers in Ang II injury in vitro | 85 |
| Genetic | Mechanism | Effect | Ref |
| SLC34a1-Cre Wnt1 Overexpression | Inducible and sustained Wnt1 production only in proximal tubular epithelium | Caused interstitial fibrosis by activation of myofibroblasts without induction by injury | 69 |
| Ksp-Cre β-catenin Stabilization | β-catenin stabilized (i.e. activated) in tubular epithelium by removing phosphorylation sites that target b-catenin for degradation | Caused increased inflammatory infiltration in protein overload injury model | 73 |
| Wnt9a Overexpression | Overexpression of Wnt9a by delivery of DNA expression plasmids | Increased tubular cell senescence and worsened fibrosis in IRI model of CKD | 70 |
| Ksp-Cre Wntless Deletion | Wntless ablated in tubular epithelium, preventing secretion of Wnts | Reduced fibrosis and fibroblast activation in UUO and UIRI models of CKD | 71 |
| Gli1-Cre β-catenin Stabilization | β-catenin stabilized (i.e. activated) selectively in Gli1+ fibroblasts | Activation of myofibroblasts in uninjured kidney | 27 |
Both the pharmacologic and genetic approaches to modulate Wnt/β-catenin signaling in chronic kidney disease are listed as well as mechanism of action, effect on renal injury, and relevant reference. Abbreviations: CBP, cAMP response element-binding (CREB) binding protein; IRI, ischemia-reperfusion injury; UUO, unilateral ureteric obstruction; CKD, chronic kidney disease; DKK-1, Dickkopf-1; LRP5/6, low density lipoprotein (LDL) receptor related protein 5/6; sFRP4, secreted Frizzled-related protein 4; Ang II, angiotensin II; SLC34a1, solute carrier family 34 member 1; Ksp, kidney-specific cadherin.